4ea93d27-97e3-40bd-8734-d026e48fbbe4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- PANCREAS_BETA_CELLS+0.400
- HYPOXIA+0.300
- MYC_TARGETS_V1+0.300
- ADIPOGENESIS+0.200
- HEDGEHOG_SIGNALING+0.200
- MTORC1_SIGNALING+0.200
- PROTEIN_SECRETION+0.200
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.200
- TNFA_SIGNALING_VIA_NFKB+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- E2F_TARGETS-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MITOTIC_SPINDLE-0.400
- ALLOGRAFT_REJECTION-0.300
- G2M_CHECKPOINT-0.300
- NOTCH_SIGNALING-0.300
- APICAL_JUNCTION-0.200
- APICAL_SURFACE-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-01632 | — | cohortA4 | 0.808 |
| 2 | SRR10899980 | — | — | 0.771 |
| 3 | MNG999 | — | — | 0.762 |
| 4 | TCGA-CQ-6228-01A-11R-1915-07 | — | — | 0.730 |
| 5 | MBCProject_0755_T1_RNA | — | B | 0.715 |
| 6 | R148 | — | — | 0.708 |
| 7 | TCGA-AQ-A04L-01B-21R-A10J-07 | — | C | 0.705 |
| 8 | TCGA-AO-A12G-01A-11R-A10J-07 | — | A | 0.688 |
| 9 | 8f673a13-7f81-4685-a415-645ff6b5e2fb | — | — | 0.682 |
| 10 | MNG624 | — | — | 0.680 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |